50
Participants
Start Date
November 1, 2025
Primary Completion Date
June 30, 2026
Study Completion Date
July 31, 2026
MUD Management (contingency management +/- adjunctive MUD pharmacotherapy)
Management of MUD will be individualized for each study patient. All patients will receive behavioral counseling utilizing motivational interviewing and education and offered a contingency management (CM) plan incentivizing abstinence from meth. Several pharmacotherapies are recommended for the treatment of MUD: mirtazapine, bupropion and naltrexone, or bupropion monotherapy. If required, adjunctive MUD pharmacotherapy will be added to the CM guided by comorbid conditions, patient characteristics, and characteristics of use.
HF GDMT management
As per standard clinical care, patients will be followed by a cardiologist for HF management including assessment for GDMT optimization.
Los Angeles General Medical Center, Los Angeles
University of Southern California, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Los Angeles
Los Angeles General Medical Center
OTHER
University of Southern California
OTHER